文献速递血脂与心血管预防冠心病

二十碳五烯酸乙酯减少总缺血事件:REDUCE-IT研究分析

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
PubMed 文献 · J Am Coll Cardiol · 2019-03-18

REDUCE-IT预先设定分析纳入8,179例他汀治疗且甘油三酯升高的患者,比较二十碳五烯酸乙酯(4 g/日)与安慰剂对总缺血事件的影响。中位随访4.9年,二十碳五烯酸乙酯显著减少主要复合终点总事件(每1,000患者年61 vs 89,率比0.70,95%CI 0.62-0.78,P<0.0001)及关键次要终点总事件。

要点

  • 在甘油三酯升高且已接受他汀治疗的患者中,二十碳五烯酸乙酯减少首次及后续缺血事件。
  • 主要复合终点总事件率比为0.70(95%CI 0.62-0.78,P<0.0001),各组分总事件亦减少。
  • 关键次要终点总事件率比为0.72(95%CI 0.63-0.82,P<0.0001)。

核心结论

  • 在甘油三酯升高且接受他汀治疗、有动脉粥样硬化性疾病或糖尿病的患者中,二十碳五烯酸乙酯显著减少首次、后续及总缺血事件负担。

研究设计与样本

  • REDUCE-IT为随机对照试验,纳入8,179例他汀治疗且甘油三酯≥135且<500 mg/dl(中位216 mg/dl)、LDL-C>40且≤100 mg/dl(中位75 mg/dl)的患者,随机接受二十碳五烯酸乙酯4 g/日或安慰剂。
  • 患者中71%有动脉粥样硬化病史,29%有糖尿病;中位随访4.9年。
  • 总事件分析采用负二项回归等预设统计方法。

主要发现

  • 共发生1,606例(55.2%)首次主要终点事件和1,303例(44.8%)后续主要终点事件(包括762例第二次事件和541例第三次及以上事件)。
  • 主要复合终点总事件率:二十碳五烯酸乙酯组61/1,000患者年 vs 安慰剂组89/1,000患者年,率比0.70(95%CI 0.62-0.78,P<0.0001)。
  • 关键次要复合终点总事件率:二十碳五烯酸乙酯组32/1,000患者年 vs 安慰剂组44/1,000患者年,率比0.72(95%CI 0.63-0.82,P<0.0001)。

关键数值与推荐

  • 主要复合终点包括心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或不稳定心绞痛住院。
  • 关键次要复合终点包括心血管死亡、非致死性心肌梗死或非致死性卒中。
  • 二十碳五烯酸乙酯4 g/日用于他汀治疗且甘油三酯≥135且<500 mg/dl、LDL-C>40且≤100 mg/dl的患者。

临床怎么用

  • 对于他汀治疗后甘油三酯仍升高(≥135且<500 mg/dl)且伴动脉粥样硬化性疾病或糖尿病的患者,可考虑加用二十碳五烯酸乙酯4 g/日以减少总缺血事件。
  • 评估获益时应关注总事件负担,而不仅是首次事件。

局限性

  • 总事件分析为预先设定但属探索性分析,需结合主要首次事件分析解读。
  • 研究纳入特定甘油三酯和LDL-C范围的患者,结果不能外推至其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These patients are at risk for not only first but also subsequent ischemic events. OBJECTIVES: Pre-specified analyses determined the extent to which icosapent ethyl reduced total ischemic events. METHODS: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated patients with triglycerides ≥135 and <500 mg/dl (median baseline of 216 mg/dl) and low-density lipoprotein cholesterol >40 and ≤100 mg/dl (median baseline of 75 mg/dl), and a history of atherosclerosis (71% patients) or diabetes (29% patients) to icosapent ethyl 4 g/day or placebo. The main outcomes were total (first and subsequent) primary composite endpoint events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) and total key secondary composite endpoint events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). As a pre-specified statistical method, we determined differences in total events using negative binomial regression. We also determined differences in total events using other statistical models, including Andersen-Gill, Wei-Lin-Weissfeld (Li and Lagakos modification), both pre-specified, and a post hoc joint frailty analysis. RESULTS: In 8,179 patients, followed for a median of 4.9 years, 1,606 (55.2%) first primary endpoint events and 1,303 (44.8%) subsequent primary endpoint events occurred (which included 762 second events, and 541 third or more events). Overall, icosapent ethyl reduced total primary endpoint events (61 vs. 89 per 1,000 patient-years for icosapent ethyl versus placebo, respectively; rate ratio: 0.70; 95% confidence interval: 0.62 to 0.78; p < 0.0001). Icosapent ethyl also reduced totals for each component of the primary composite endpoint, as well as the total key secondary endpoint events (32 vs. 44 per 1,000 patient-years for icosapent ethyl versus placebo, respectively; rate ratio: 0.72; 95% confidence interval: 0.63 to 0.82; p < 0.0001). CONCLUSIONS: Among statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially reduces the burden of first, subsequent, and total ischemic events. (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial [REDUCE-IT]; NCT01492361).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019. PMID: 30898607. doi:10.1016/j.jacc.2019.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。